Business Wire

CA-VELODYNE-LIDAR,-INC.

15.11.2018 14:02:11 CET | Business Wire | Press release

Share
Automotive Innovator, Rick Tewell, Promoted to Chief Operating Officer at Velodyne Lidar

Velodyne Lidar, Inc. announces the promotion of Rick Tewell to Chief Operating Officer. Tewell assumes leadership of the company’s vast manufacturing efforts at its Megafactory in San Jose, California. He joined the company in September 2017 as Senior Vice President of Automated Manufacturing and was promoted to Chief Advanced Manufacturing Officer prior to the promotion to COO. He brings a wealth of expertise to the day-to-day production of Velodyne’s industry-leading lidar sensor product line.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005168/en/

According to Marta Hall, Velodyne’s President and Chief Business Development Officer, Velodyne “recruited Rick Tewell to manage Robotics and Advanced Technology, and within a year it was clear he could lead Operations as COO. Velodyne Lidar is at the extreme edge of high tech, and Rick meets the challenge with da Vinci-like multiple talents. In the last three months Rick upgraded the entire Velodyne Megafactory with robotics and newly designed innovative processes for production. As COO he brings a futuristic vision and fresh energy to the operations of the company.”

“My main responsibility,” said Tewell, “is to take a design that came from the mind of a genius, David Hall [Velodyne’s Founder and CEO], and make it into a product worthy of the Velodyne name. I work with David and Anand [Gopalan, Velodyne’s Chief Technology Officer] to translate these wonderful designs that have the ability to change the world into something that is manufacturable and then ramp production to meet the demand. To take an invention from Dave Hall and turn it into a manufacturable product is a huge responsibility and one that I take very seriously. It’s an incredible opportunity. I get out of bed excited to go to work, and I go to bed thinking about it.”

According to Tewell, the job of Chief Operating Officer at Velodyne is unlike any other. Between designing and manufacturing the highest quality sensors on the market comes the equally challenging task of inventing and building the machines that then build the sensors.

“For our sensors to be able to see so far and produce incredibly accurate data for autonomous vehicles to use, we have to employ incredibly precise processes, which include utilizing robotics and automation. So we need to also invent the machines that will build our sensors.” Given the uniqueness of Velodyne’s products, Tewell pointed out that he must address the complex processes of “taking something that’s never been invented or built before and building tens of thousands -- hundreds of thousands -- millions of them. It is a whole series of inventions to produce the sensor invention. So, it is not just the genius of the lidar itself; it’s the genius of saying, ‘This is what you are going to need to invent in order to manufacture the sensor.’”

Before coming to Velodyne, Tewell established a successful career in the automotive semiconductor industry, including stops at Fujitsu and NVIDIA. Rick remembers, “The idea that cars eventually would be robots emerged while Dave Hall was participating in the DARPA Grand Challenge. At NVIDIA we were creating the brains that would be used in self-driving cars.” Tewell’s interest and experience in developing key technologies for autonomous mobility grew over the years. Finally, Tewell decided to join Velodyne with the clear realization that he would be “aligning with a company that will be one of, if not the, principal company in the self-driving industry.”

Tewell recognizes the essential role Velodyne’s products have in enabling safe mobility at scale. “We are working hard to meet the next wave of demand for sensors to put on autonomous vehicles. Scaling up will drive the cost down to where the price is attractive to all customers. But we will never compromise on quality. It is critical from an operations standpoint that our product will ultimately impact someone’s life. This realization needs to permeate every aspect of what we do. This is not a piece of technology that is going to stay in a box. When you put a sensor on a car the person in that car is trusting that technology to keep them safe.”

About Velodyne Lidar

Founded in 1983 and headquartered in Silicon Valley, Velodyne is a technology company known worldwide for its real-time 3D lidar computing and software platforms. The company evolved after founder David Hall invented the HDL-64 Solid-State Hybrid lidar sensor in 2005. Since then, Velodyne Lidar, Inc. emerged as the unmatched market leader of real-time 3D vision systems used in a variety of commercial applications including autonomous vehicles, vehicle safety systems, mobile mapping, aerial mapping, and security. Its products range from the high-performance, surround view Ultra-Puck™ VLP-32, classic HDL-32/64 and cost-effective VLP-16, the new VLS-128, to the upcoming, hidden Velarray™. Velodyne’s rich suite of perception software and algorithms are the key enablers of its perception systems. Velodyne supports customers from offices in San Jose, Detroit, Frankfurt, and Beijing. For more information, visit http://www.velodynelidar.com .

Contact:

David Cumpston Landis Communications for Velodyne Lidar, Inc. (415) 359-2316 velodyne@landispr.com

Social Media:

https://www.facebook.com/velodyneLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye